ViroPharma Whacked by Data

Hopefully drug developer ViroPharma (Nasdaq: VPHM  ) was only on everyone's watch list today as shares were down more than 18% following the announcement that it was halting dosing of its hepatitis C antiviral compound in a phase 2 study.

ViroPharma's hepatitis C drug candidate, HCV-796, is being developed with partner Wyeth (NYSE: WYE  ) . Of all the HCV polymerase inhibitor drug candidates it was the furthest along in testing after Idenix Pharmaceuticals' (Nasdaq: IDIX  ) polymerase inhibitor failed in a phase 2 study two months ago.

What led ViroPharma and Wyeth to end dosing of HCV-796 was that 8% of patients taking the drug in the phase 2 study were experiencing higher liver enzyme levels compared to only 1% of patients in the standard of care arm of the study.

Elevations of liver enzymes are a concern for any drug because they often are an early indicator of liver-related disorders if whatever is causing the raised enzyme levels is not corrected. That this issue didn't show up in earlier human studies of HCV-796 is likely due to the short-term nature of the studies and the fact that hepatitis C is a disease that adversely affects the liver by itself.

If there is a small sliver of hope from the study results announced today, it is that HCV-796 was highly active in eliminating HCV for genotype-1 patients who have previously failed treatment with the standard of care. Twenty-three percent of those null responders (as ViroPharma calls them) had undetectable levels of the virus in their bodies after only 12 weeks of treatment. Undetectable hepatitis C viral loads are a strong indicator of later being declared cured of the disease; currently there are no good treatment options for these non-responder patients.

As the FDA likes to point out, though, raised liver enzyme levels are the No. 1 cause of all drug adverse events and, more worryingly, all new drug application rejections. At best, these results suggest that any path forward for HCV-796 would be as a second-line agent for hepatitis C genotype-1 patients failing existing therapies.

There is still a long-shot possibility for the drug if the liver enzyme issues can be corrected or reduced in future studies. Examples of possible solutions include either lowering the dosing of HCV-796 or shortening the treatment duration, but investors shouldn't hold their breath that the drug will remain in development.

These safety issues are definitely a major setback for HCV-796 but it's also worth noting that shares of ViroPharma are at dirt cheap levels right now. The company has a market cap of $580 million with operating income of at least $100 million expected this year and over $260 million in net cash as of the end of the second quarter.

Looking for more Foolish drug stock coverage? Check out the Fool's market-beatingRule Breakers newsletter. You can see all our recommendations as well as get access to our message boards and exclusive content with a 30-day free trial.

Fool contributor Brian Lawler does not own shares of any company mentioned in this article. The Fool has a disclosure policy.


Read/Post Comments (0) | Recommend This Article (10)

Comments from our Foolish Readers

Help us keep this a respectfully Foolish area! This is a place for our readers to discuss, debate, and learn more about the Foolish investing topic you read about above. Help us keep it clean and safe. If you believe a comment is abusive or otherwise violates our Fool's Rules, please report it via the Report this Comment Report this Comment icon found on every comment.

Be the first one to comment on this article.

Sponsored Links

Leaked: Apple's Next Smart Device
(Warning, it may shock you)
The secret is out... experts are predicting 458 million of these types of devices will be sold per year. 1 hyper-growth company stands to rake in maximum profit - and it's NOT Apple. Show me Apple's new smart gizmo!

DocumentId: 533750, ~/Articles/ArticleHandler.aspx, 12/17/2014 8:03:01 PM

Report This Comment

Use this area to report a comment that you believe is in violation of the community guidelines. Our team will review the entry and take any appropriate action.

Sending report...


Advertisement